Paradigm Biopharmaceuticals Advances Osteoarthritis Program with Peer-Reviewed Validation of Injectable PPS
核心洞察
Paradigm Biopharmaceuticals (搜索) achieved peer-reviewed publication of Phase 2 biomarker study results for injectable pentosan polysulfate sodium (iPPS) in moderate to severe knee osteoarthritis (搜索) patients.
The study demonstrated significant reductions in cartilage degradation biomarkers directly in synovial fluid, with effects persisting months after treatment ended.
Complementary canine osteoarthritis (搜索) research published in PLOS One showed sustained pain reduction and structural joint benefits through 26 weeks following six-week PPS treatment.
Paradigm Biopharmaceuticals (搜索) has strengthened its osteoarthritis (搜索) development program with the peer-reviewed publication of Phase 2 biomarker study results investigating injectable pentosan polysulfate sodium (iPPS) in patients with moderate to severe knee osteoarthritis. The manuscript, published in Arthritis Research and Therapy, provides independent validation of iPPS's biological activity in the osteoarthritic joint and reinforces the scientific rationale for the company's ongoing Phase 3 clinical program.
Phase 2 Human Biomarker Study Demonstrates Joint-Level Activity
The PARA_OA_008 study was designed as an exploratory, randomised, double-blind, placebo-controlled Phase 2 trial with an unusually detailed biomarker strategy, including repeated ultrasound-guided synovial fluid sampling, along with blood and urine analyses. The primary purpose was to examine whether iPPS produces measurable biological effects on disease-relevant pathways in osteoarthritis (搜索) rather than demonstrate clinical efficacy for regulatory approval.
Patients treated with iPPS showed significant reductions in biomarkers associated with cartilage degradation. Levels of synovial fluid ARGS (搜索), a marker of aggrecan breakdown in cartilage, were significantly reduced compared with placebo by Day 56 and remained lower through Day 168. Similarly, serum C2C (搜索), a marker of type II collagen degradation, was reduced at later time points, indicating a broader effect on cartilage metabolism.
The study revealed changes in markers linked to bone and cartilage turnover, with serum CTX-I (搜索) increasing in the iPPS group, suggesting altered tissue remodelling processes consistent with biological engagement rather than simple symptomatic relief. Inflammation-related biomarkers within the joint also shifted favorably, with key inflammatory mediators such as TNF-α (搜索) and IL-6 reduced, while TIMP-1 (搜索), an endogenous inhibitor of cartilage-degrading enzymes, increased.
Synovial Fluid Analysis Provides Direct Evidence
One of the most significant aspects of the study is that many of the observed biomarker changes were detected directly in synovial fluid, the biological environment within the knee joint itself. Because synovial fluid sits at the centre of osteoarthritis (搜索) pathology, changes measured there provide strong evidence that a therapy is acting locally at the site of disease.
Reductions were also observed in nerve growth factor (NGF), a biomarker closely linked to pain sensitisation in osteoarthritis (搜索), providing a biological explanation for clinically observed pain improvements and connecting molecular findings with patient-reported outcomes. Several of these biomarker effects persisted months after dosing ended, suggesting that iPPS may induce durable biological changes rather than transient pharmacological effects.
Translational Canine Study Supports Long-Term Benefits
Complementing the human data, Paradigm published peer-reviewed results in PLOS One demonstrating sustained pain reduction, functional improvement, and structural joint benefits from pentosan polysulfate sodium (PPS) in naturally occurring canine osteoarthritis (搜索). The study reported durable effects through 26 weeks following a six-week treatment course, with outcomes spanning clinical pain scores, objective gait analysis, magnetic resonance imaging, and serum biomarkers.
The randomised, placebo-controlled translational study in companion dogs with radiographically confirmed, naturally occurring osteoarthritis (搜索) affecting the stifle and/or elbow joints involved weekly subcutaneous dosing of PPS for six weeks, with follow-up assessments conducted through week 26.
After adjustment for higher baseline pain in the treatment group, PPS-treated dogs demonstrated sustained reductions in Helsinki Chronic Pain Index scores to six months, while placebo-treated dogs showed worsening pain. Objective gait analysis showed progressive normalisation of gait symmetry at weeks eight and 26, consistent with improved weight-bearing and reduced lameness.
Structural Disease-Modifying Evidence
Quantitative magnetic resonance imaging demonstrated stabilisation and modest increases in total cartilage volume in PPS-treated dogs at weeks eight and 26 relative to baseline. In contrast, placebo-treated dogs continued to show cartilage volume loss over the same period, supporting a potential structural disease-modifying effect.
Serum biomarkers showed reduced bone resorption, with CTX-I (搜索) levels declining and a statistically significant treatment effect observed at week 26. Additional biomarker changes included reductions in hyaluronic acid and increases in TIMP-1 (搜索), collectively consistent with slowed cartilage degradation and altered joint tissue turnover.
Clinical Development Implications
Dr Donna Skerrett, Paradigm's Chief Medical Officer and first author of the human study manuscript, highlighted that conducting a trial involving repeated synovial fluid sampling and complex biomarker analysis required extensive collaboration among investigators, laboratories, and the company's clinical team. The peer-reviewed findings provide valuable insight into how iPPS may act within the osteoarthritic joint and further validate the company's development strategy.
Dr Catherine Stapledon, lead author of the canine study and Paradigm's translation research manager, noted that evaluating PPS in dogs with naturally occurring osteoarthritis (搜索), rather than in induced laboratory models, provides a clinically relevant translational bridge to human disease. The six-month follow-up in this setting offers insight into longer-term biological and structural effects that would typically require several years to assess in people.
The combined human and canine datasets provide complementary evidence that PPS influences key pathways linked to inflammation, cartilage degradation, pain signalling, and joint remodelling, strengthening the scientific and regulatory foundation supporting Paradigm's ongoing Phase 3 injectable PPS program.